← Back to Clinical Trials
Recruiting NCT04463160

NCT04463160 Study of the Factors Favoring the Transition From Prediabetes to Diabetes on Reunion Island.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04463160
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de la Réunion
Condition Diabetes
Study Type INTERVENTIONAL
Enrollment 2,000 participants
Start Date 2019-07-18
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
prevention program for prediabetes "Say No to Diabetes"

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 2,000 participants in total. It began in 2019-07-18 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The management of diabetes and its complications in Reunion island is one of the priority areas of health. Indeed, the impact of diabetes on the health of the Reunion island population is major: the prevalence of diabetes treated in Reunion island is the highest in France (10% of the population), and gestational diabetes is found in 10% of pregnancies. Reunionese diabetics develop severe complications, in particular cardiovascular (strokes, myocardial infarction). This results in 3 times higher mortality linked to diabetes on Reunion Island, in particular among those under 65 years of age. Despite all the screening and prevention programs put in place, the weight of diabetic disease continues to increase in our island, and this is more accelerated than in the other French departments with 4,300 new cases of diabetes / year, 95% of which type 2 diabetics (T2D). The presentation of type 2 diabetic patients in Reunion island also differs from the Metropolis with subjects more often female (56%), thinner and younger at the discovery of diabetes. These data highlight the need to better understand the factors underlying the diabetes "epidemic" in Reunion island. The rise in blood sugar until the onset of diabetes is a continuous phenomenon reflecting the progressive suffering of the organs used to maintain carbohydrate homeostasis. Thus, we talk about fasting hyperglycemia when the fasting blood sugar is between 1.10 and 1.25 g / L (6.1-6.9 mmol / l) and glucose intolerance when the blood sugar 2 hours after taking 75 g of glucose is between 1.40 and 1.99 g / L (7.8-11.0 mmol / l). Subjects with fasting hyperglycemia or glucose intolerance constitute the target population at very high risk of developing diabetes (up to 70% of these subjects). They have an increased risk of developing diabetes at 1 year multiplied by 5 to 10 compared to normoglycemic subjects, hence the name "prediabetic subjects". This great variability in the risk of developing diabetes highlights the presence of associated risk / protective factors which it is important to find in order to adapt the monitoring and management. It is important in Reunion island, in view of the specificities presented by our population, to understand the pre-diabetes / diabetes transition and the risk and protective factors.

Eligibility Criteria

Inclusion Criteria: * Subject aged 25 to 70 with pre-diabetes defined by fasting blood sugar between 1.10 and 1.25 g / l (6.1 and 6.9 mmol / l) or blood sugar between 1.40 and 1.99 g / l (7.8 and 11.0 mmol / l) 2 hours after taking 75g of glucose (HGPO test), dating from less than 3 months. * Consulting one of the general practitioners involved in the study, whatever the initial reason for the consultation * able to answer a telephone survey questionnaire * who have never been diagnosed or treated for diabetes with the exception of gestational diabetes * Person affiliated or beneficiary of a social security scheme. * Free, informed and written consent signed Exclusion Criteria: * People likely to leave Reunion within 2 years * Persons placed under guardianship, curators, safeguard of justice, person participating in another research including an exclusion period still in progress. * Person with severely impaired physical and / or psychological health, who, according to the investigator, may affect the compliance of the study participant. * Pregnancy in progress

Contact & Investigator

Central Contact

Samir MEDJANE

✉ samir.medjane@chu-reunion.fr

📞 0262359750

Frequently Asked Questions

Who can join the NCT04463160 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 70 Years, studying Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04463160 currently recruiting?

Yes, NCT04463160 is actively recruiting participants. Contact the research team at samir.medjane@chu-reunion.fr for enrollment information.

Where is the NCT04463160 trial being conducted?

This trial is being conducted at Saint-Pierre, France.

Who is sponsoring the NCT04463160 clinical trial?

NCT04463160 is sponsored by Centre Hospitalier Universitaire de la Réunion. The trial plans to enroll 2,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology